Sales and Marketing

Showing 15 posts of 11524 posts found.

Don’t replace NICE with another ‘misguided experiment’

November 5, 2010 Sales and Marketing NHS, NICE, Stockholm Network, medicines access, risk-sharing

Replacing NICE with a similar system would be detrimental to UK healthcare, according to the Stockholm Network, which further warns …

NicOx to halve HQ workforce

November 4, 2010 Research and Development, Sales and Marketing NicOx, job cuts, naproxcinod, pharma jobs

French pharmaceutical company NicOx is to halve the workforce at its Sophia Antipolis headquarters and is considering restructuring its Italian …

Biogen set to axe 650 jobs and focus on neurology

November 4, 2010 Research and Development, Sales and Marketing Biogen, Rituxan, job cuts, pharma jobs

Biogen Idec is set to cut hundreds of jobs and refocus its R&D in an effort to cut costs by …
ABPI Code of Practice

UK pharma to declare doctor payments

November 4, 2010 Medical Communications, Sales and Marketing ABPI, ABPI Code of Practice, advisory boards, healthcare professionals, pharma industry standards

Pharma companies in the UK have agreed to restrict their promotional giveaways and to declare payments to doctors. Another common …

Doctors.net.uk boosts business development team

November 4, 2010 Sales and Marketing Doctors.net.uk, Jo Bell, Lizzie Evans, Paul Kelly, Phil Oldroyd, appointment, sales and marketing

Online healthcare professional network Doctors.net.uk has made three business development appointments and added a new project manager to its team. …

New Commercial Realities

November 4, 2010 Sales and Marketing Kinapse, White paper

Faced with a changing healthcare environment and the prospect of diminishing commercial returns, pharmaceutical companies must undertake a fundamental and …

Lundbeck issues Lexapro patent warning

November 3, 2010 Sales and Marketing Azilect, Cipralex, Forest Laboratories, Lexapro, Lundbeck, Xenazine

Neurological disorder specialist Lundbeck has posted a modest growth in revenue for the third quarter, but warned the looming patent …

Pfizer Q3 profits hit hard

November 3, 2010 Sales and Marketing Liptior sales, Pfizer, Pfzier Q3 results, Wyeth

The integration of Wyeth into Pfizer continues to drive its revenue growth, but at a cost – charges from the …

Nycomed expands China presence with Techpool stake

November 2, 2010 Research and Development, Sales and Marketing China, Guangdong Techpool biopharma, Nycomed, emerging markets, emerging pharma markets

Swiss-based Nycomed has acquired a majority stake in Guangdong Techpool biopharma in China, extending its presence in the top tier …

Lundbeck UK appoints senior management team

November 2, 2010 Research and Development, Sales and Marketing Amanda Badrick, Andy Davis, Andy Jones, Helen Carberry, Lundbeck, Steve Ferguson, appointment, recruitment, research and development, sales and marketing

Lundbeck UK has formed a new senior management team, appointing Steve Ferguson, Andy Davis, Andy Jones, Helen Carberry and Amanda …

Regulators must catch up with medical science, says FDA

November 2, 2010 Research and Development, Sales and Marketing Advancing Regulatory Science, Critical Path Initiative’, Dr Margaret Hamburg, FDA, regulatory affairs

The head of the FDA has declared a need for ‘regulatory science’ to catch up with the advances in medical …

FDA approves Novartis’ Afinitor

November 1, 2010 Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis

Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …

Pfizer to seek US approval for crizotinib next year

November 1, 2010 Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer

Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …

German rebates to cost pharma 1 billion euro

November 1, 2010 Sales and Marketing BPI, German pharma market, Germany, Gesetzliche Krankenversicherung, healthcare costs

The pharma industry will contribute over 1 billion euro ($1.4 billion) to Germany’s cost-containment efforts by the end of 2010. …

GSK signs rare diseases deal with Amicus

November 1, 2010 Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones

GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …
The Gateway to Local Adoption Series

Latest content